News Releases
- Algernon Begins Screening Patients for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia July 7, 2020
- Algernon Pharmaceuticals Announces Extension of Exercise Date of Warrants July 7, 2020
- Algernon Receives Ethics Approval for U.S. Sites for 2b/3 Human Study of Ifenprodil for COVID-19 June 25, 2020
- Algernon Pharmaceuticals Announces Deemed Exercise of Special Warrants June 12, 2020
- Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19 June 4, 2020
- Algernon Pharmaceuticals Discusses Multinational Phase 2b/3 Ifenprodil COVID-19 Human Trial on BioPub Webcast Hosted by Dr. KSS MD PhD May 28, 2020
- Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19 May 26, 2020
- Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19 May 25, 2020
- Algernon Submits for Ethics Approval in Australia for Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19 May 15, 2020
- Algernon Announces Closing of $6.8 Million Private Placement Offering, Including Exercise of the Over-Allotment Option May 13, 2020